A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any relationship, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of these, ** (See formula) ** in wherein ring A is a 5-membered, 6-membered or 7-membered cycloalkane ring, a benzene ring or a 5-membered or 6-membered monocyclic aromatic heterocyclic ring comprising 1 or 2 identical or different hetero ring members chosen from the series consisting of N and S, in which the cycloalkane ring is optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine and alkyl- (C1-C4), and the benzene ring and the heterocyclic rings are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, alkyl- (C1-C4), alkyl- (C1-C4) -Oy NC-； Y is chosen from the series consisting of S, C (R12)>； = C (R13), N>； = C (R14) and C (R15)>； = N； Z is chosen from the series consisting of N and C (R16)； R30, R33, R35, R54, R55, R57 and R58, regardless of each distinct group R30, R33, R35, R54, R55, R57 and R58, are chosen from the series consisting of alkyl- (C1-C6), alkenyl - (C2-C6), alkynyl- (C2-C6), cycloalkyl- (C3-C7) and cycloalkyl- (C3-C7) -alkyl- (C1-C4) - which are all optionally substituted by one or more identical substituents or different R70； R3 and R5 are independently selected from each other from the series consisting of hydrogen, alkyl- (C1-C4), phenyl-alkyl- (C1-C4) -, phenyl and hydroxy； R4 and R6 are independently selected from each other from the series consisting of hydrogen and alkyl- (C1-C4)； R12, R13, R14, R15 and R16 are independently selected from each other from the series consisting of hydrogen, halogen, alkyl- (C1-C4) -, alkyl- (C1-C4) -O- and NC-； R20 is chosen from the series consisting of hydrogen and alkyl- (C1-C4)； R21 is chosen from the series consisting of halogen, R30, HO-, R30-O-, R30-C
